MedMen, US cannabis giant, set to become one of the largest Canadian-listed cannabis companies

The company, which began trading on the Canadian Securities Exchange today, has a fast-growing footprint that could redefine and modernize the Canadian cannabis retail space
MedMen, US cannabis giant, set to become one of the largest Canadian-listed cannabis companies
Cannabis company MedMen Enterprises has a $1.65bln valuation

MedMen Enterprises Inc (CSE:MMEN), one of the fastest-growing companies in the US cannabis industry, started trading today on the Canadian Securities Exchange (CSE).

With more than 800 employees, the company – with its sleek, modern Apple-esque retail stores – operates 18 licensed facilities in California, Nevada and New York. The importance of these three states? They account for around half the addressable cannabis market in the US.

US companies look north

US cannabis companies are increasingly looking to Canadian markets as they raise money. Not to mention the fact that MedMen also intends to enter the Canadian recreational marijuana market when legal – a move that could pivot MedMen into a leadership position in the country.

“MedMen’s vision is simple but revolutionary: cannabis as a consumer product,” said MedMen Co-founder and CEO Adam Bierman. “For the better part of a decade we have been singularly focused on that vision – creating the systems and infrastructure that raise the bar on product quality and safety and providing a retail shopping experience that is second to none. By going public, MedMen gives investors a ground-floor opportunity to participate in the enormous and untapped potential of the fastest growing industry in the United States.”

Currently, state-sanctioned sales of cannabis in the US are estimated to be US$7 billion annually – expected to reach US$75 billion by 2030, according to financial services firm, the Cowen Group.

"Our listing on the CSE will give MedMen greater flexibility in accessing capital in the public equity markets to leverage our first-mover advantage and to build upon our track record of growth," Bierman said.

Canadian partners

This March, MedMen announced a joint venture with Canadian licensed producer, Cronos Group. The aim is to bring the MedMen retail experience to Canada, in provinces such as British Columbia and Alberta, where private retail stores will be allowed.

"We are making marijuana mainstream by making it okay for soccer moms and middle-aged professionals to use cannabis products," said MedMen co-founder and president Andrew Modlin. "People are using it for ailments, for wellness or to just relax or socialize with friends... We are marching steadily toward a future where buying and using cannabis products will be just as normal as buying wine or beer."

Shares of MedMen were C$5.15 on Tuesday.

View full MMEN profile View Profile

Related Articles

Vial of pills
May 17 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
picture of cannabis plants
March 23 2018
Control of the supply chain offers operational advantages and financial benefits.
researcher filling a vial
April 23 2018
2018 is shaping up to be a crucial year for the company's drug pipeline

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated.